Kuros Biosciences (LTS:0RHR) 10-Year Share Buyback Ratio : -50.50% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Kuros Biosciences 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Kuros Biosciences's current 10-Year Share Buyback Ratio was -50.50%.

LTS:0RHR's 10-Year Share Buyback Ratio is ranked worse than
94.84% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: -3.9 vs LTS:0RHR: -50.50

Competitive Comparison of Kuros Biosciences's 10-Year Share Buyback Ratio

For the Medical Devices subindustry, Kuros Biosciences's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences's 10-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Kuros Biosciences 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Kuros Biosciences (LTS:0RHR) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Kuros Biosciences 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (LTS:0RHR) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK KURN:Switzerland

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.

Kuros Biosciences Headlines

No Headlines